亚洲社会药学

主编：黄泰康

《亚洲社会药学》是由沈阳药科大学主办，香港盛京药大出版传媒有限公司负责出版发行的药学类英文季刊。本刊主要以世界各地药学研究人员、药师、政府部门工作人员、医药院校等相关教学人员为主要读者，主要刊登内容包括：政治、经济、社会文化、技术、自然等环境因素的变化对药学领域组织、个人及患者行为的影响；人口数量与结构的改变、疾病谱的变化、药品消费心理与行为的变化趋势，以及药学组织的行为如何适应这些变化、满足社会需求；社会用药的特点、规律以及所产生的社会问题；全社会医药资源的优化配制与高效利用；药事法规及药品政策应发挥的主要作用；药学伦理、药学工作者的职业道德以及医患关系、病人的依从性；影响合理用药的社会与人文因素；药学教育和咨询服务；国内外社会药学研究的新进展及最新研究成果等等。本刊论文发表不需版面费。.. More

ISSN: 1818-0884

Application of Real-World Evidence in the Approval of Antitumor Drugs

Shang Ya’nan, Huang Zhe

2024, 19 (4): 311–318;

摘要 ( 12 ) PDF (455KB) ( 6 )

Analysis of Innovations in Monitoring Adverse Drug Reaction and Application

Gong Jingyu, Tian Lijuan

2024, 19 (4): 319–326;

摘要 ( 3 ) PDF (361KB) ( 3 )

Research on the Construction of Drug Inspection Evaluation Indicator System

Hu Di, Liao Ping, Zhu Xin, Dai Yuemin, Ge Yuanyuan, Chen Yuwen

2024, 19 (4): 327–343;

摘要 ( 5 ) PDF (457KB) ( 2 )

Implementation of the Guidelines for Oncolytic Viruses in China

Meng Qinghe, Wang Shuling, Yang Mo

2024, 19 (4): 344–350;

摘要 ( 7 ) PDF (370KB) ( 2 )

Research on the Impact of the Centralized Drug Procurement Policy on China’s Pharmaceutical Enterprises

Miao Li, Tian Lijuan

2024, 19 (4): 351–360;

摘要 ( 6 ) PDF (1127KB) ( 2 )

Research on the Influence of Government R&D Funding and Enterprise R&D Investment on the Innovation Efficiency of Pharmaceutical Industry

Zhang Xuefeng, Jia Zheng, Fu Shuyong, Zhang Dawei, Xing Hua

2024, 19 (4): 361–370;

摘要 ( 2 ) PDF (453KB) ( 2 )

Analysis of Patents Related to COVID-19 - Based on Patent Clustering Model in Specific Fields

Fu Nan, Li Qian, Yuan Hongmei

2024, 19 (4): 371–382;

摘要 ( 6 ) PDF (3328KB) ( 2 )

Analysis of the Incidence and Risk Factors of Postoperative Infection in Patients with Class I Incisions Based on Literature Research

Wang Jinping, Sheng Qi, Zhao Jie, Wu Zhiang

2024, 19 (4): 383–389;

摘要 ( 8 ) PDF (469KB) ( 2 )

Visual Analysis of the Treatment for Soft Tissue Injury with TCM Based on CiteSpace

Su Haining, Duan Xiaoxiang, Wang Shuling

2024, 19 (4): 390–400;

摘要 ( 2 ) PDF (3371KB) ( 0 )

The Impact of Multimorbidity on Healthcare Utilization and Expenditure: Evidence from China

Ding Liman

2024, 19 (4): 401–408;

摘要 ( 3 ) PDF (371KB) ( 5 )